Essential oil from chenopodium ambrosioides as a promising antileishmanial agent

Natural Product Communications

Volumn 2, Issue 12, 2007, Pages 1257-1262

  Fidalgo, Lianet Monzote ^a  

^a INSTITUTO DE MEDICINA TROPICAL PEDRO KOURÍ   (Cuba)

Author keywords

Antileishmanial agent; BALB c mice; Chenopodium ambrosioides; Essential oil; Leishmaniasis

Indexed keywords

EID: 77954113651     PISSN: 1934578X     EISSN: 15559475     Source Type: Journal    
DOI: 10.1177/1934578x0700201214     Document Type: Article

References (35)

1. Bailey MS, Lockwood DNJ. (2007) Cutaneous leishmaniasis. Clinics in Dermatology, 25, 203-211.
2. Desjeux P. (2001) The increase in risk factors for leishmaniasis worldwide. Transactions of the Royal Society of Tropical Medicine and Hygiene. 95, 239-243.
3. Sereno D, Cordciro A, Mathieu-Daude F, Ouaissi A. (2007) Advances and perspectives in Leishmania cell based drug-screening procedures. Parasitology International, 56, 3-7.
4. Bennan J. (2005) Recent developments in leishmaniasis: Epidemiology, diagnosis and treatment. Current Opinion in Infectious Diseases, 7, 33-38.
5. Blum J, Desjeux P, Schwartz E, Bcck B, Hatz C. (2004) Treatment of cutaneous leishmaniasis among travelers. Journal of Antimicrobial Chemotherapy, 53, 158-166.
6. Requena JM, Iborra S, Carrion J, Alonso C, Soto M. (2004) Recent advances in vaccines for leishmaniasis. Expert Opinion in Biological Therapy, 4, 1505-1517.
7. Singh S, Sivakumar R. (2004) Challenges and new discoveries in the treatment of leishmaniasis. Journal of Infection and Chemotherapy, 10, 307-315.
8. Croft SL, Yardley V. (2002) Chemotherapy of leishmaniasis. Current Opinion in Pharmaceutical Design, 8, 319-342.
9. Pink R, Hudson A, Mouries MA, Bendig M. (2005) Opportunities and challenges in antiparasitic drug discovery. Nature Review, 4, 727-740.
10. Kaminsky R. (2002) Miltefosine. Current Opinion in Investigational Drugs, 3, 550-554.
11. Chan MJ, Pefia LM. (2001) Plant natural products with leishmanicidal activity. Natural Product Reports, 18, 674-688.
12. Fournet A, Mufioz V. (2002) Natural products as trypanocidal, antileishmanial and antimalarial Drugs. Current Topics in Medicinal Chemistry, 2, 1215-1237.
13. Franca F, Lago EL, Marsden PD. (1996) Plants used in the treatment of leishmanial ulcers due to Leishmania (Vianna) braziliensis in an endemic area of Bahia, Brazil. Revista da Sociedade Brasileira de Medicina Tropical, 29, 229-232.
14. Monzote L, Montalvo AM, Almanonni AS, Scull R, Miranda M, Abreu J. (2006) Activity of the essential oil from Chenopodium ambrosioides grown in Cuba against Leishmania amazonensis. Chemotherapy, 52, 130-136.
15. Monzote L, Garcia M, Montalvo AM, Scull R, Miranda M, Abreu J. (2007) Activity of the essential oil from Chenopodium ambrosioides against Leishmania donovani. Phytotherapy Research, 21, in press.
16. Monzote L, Montalvo AM, Scull R, Miranda M, Abreu J. (2007) Activity, toxicity and analysis of resistance of essential oil from Chenopodium ambrosioides after intraperitoneal, oral and intralesional administration in BALB/c mice infected with Leishmania amazonensis: A preliminary study. Biomedicine and Pharmacotherapy, 61, 148-153.
17. Monzote L, Montalvo AM, Scull R, Miranda M, Abreu J. (2007) Combined effect of the essential oil from Chenopodium ambrosioides and antileishmanial drugs on promastigotes of Leishmania amazonensis. Revista do Instituto de Medicina Tropical de Sao Paulo, 49, 257-260.
18. Wallace J. (2004) Antimicrobial properties of plant secondary metabolites. Proceedings of the Nutrition Society, 63, 621-629.
19. Kiuchi F, Itano Y, Uchiyama N, Honda G, Tsubouchi A, Nakajima-Shimada J, Aoki T. (2002) Monoterpene hydroperoxides with trypanocidal activity from Chenopodium ambrosioides. Journal of Natural Products, 65, 509-512.
20. MacDonald D, VanCrey K, Harrison P, Rangachari PK, Rosenfeld J, Warren C, Sorger G. (2004) Ascaridole-less infusions of Chenopodium ambrosioides contain a nematocide(s) that is(are) not toxic to mammalian smooth muscle. Journal of Ethnopharmacology, 92, 215-221.
21. Smillie WC, Pessoa SB. (1924) A study for anthelmintic properties of the constituents of the oil of Chenopodium. Journal of Pharmacology and Experimental Therapeutics, 24, 359-370.
22. Fester GA, Martinuzzi EA, Retamar JA, Ricciardi AIA. (1961) Aceites esenciales de la Replublica de Argentina. Academia Nacional de Ciencias, Cordoba, 1-76.
23. Vizoso A, Garcia A, Ramos A, Piloto J, Pavon V, Penichet M. (2000) Evaluacion mutagenica de un extracto fluido con un menstruo etanolico al 70 % de Teloxis ambrosiodes L. Weber (Apasote). Revista Cubana de Plantas Medicinales, 5, 102-105.
24. Gadano AB, Gurni AA, Lopez P, Ferraro G, Carballo MA. (2002) In vitro genotoxic evaluation of the medicinal plant Chenopodium ambrosioides. Journal of Ethnopharmacology, 81, 11-16.
25. Koutsoupakis C, Gialou I, Pavlidou E, Kapetanaki S, Varotsis C. (2002) Antimalarial endoperoxidcs: synthesis and implications of the mode of action. Arkivoc, xiii, 62-69.
26. Genestra M, Echevarria A, Cysne-Finkelstein L, Vignolio-Alves L, Leon LL. (2005) Effect of amidine derivatives on nitric oxide production by Leishmania amazonensis promastigotes and axenic amastigotes. Nitric Oxide, 8, 1 -6.
27. Singh TR, Sundar S. (2002) Identification of a gene linked to drug resistance in field isolates of Leshmania donovani. Annals of Tropical Medicine and Parasitology, 96, 839-84.
28. Carrio J, Portus M. (2002) In vitro susceptibility to pentavalent antimony in Leishmania infantum strains is not modified during in vitro or in vivo passages but is modified after host treatment with meglumine antimoniate. Pharmacology, 2, 11-15.
29. Cauchetier E, Loiseau PM, Lehman J, Rivollet D, Flcury J, Astier A, Deniau M, Paul M. (2002) Characterisation of atovaquone resistance in Leishmania infantum promastigotes. International Journal of Parasitology, 32, 1043-1051.
30. Seifert K, Matu S, Perez-Victoria FJ, Castanys S, Gamarro F, Croft SL. (2003) Characterisation of Leishmania donovani promastigotes resistant to hexadeeylphosphocholine (miltefosine). International Journal of Antimicrobial Agents, 22, 380-387.
31. Bryceson A. (2001) Current issues in the treatment of visceral leishmaniasis. Medical Microbiology and Immunology, 190, 81-84.
32. Johnson MD, MacDougall C, Ostrosky-Zeichner L, Perfect JR, Rex JH. (2004) Combination antifungal therapy. Antimicrobial Agents and Chemotherapy, 48, 693-715.
33. Baselin M, Lawrence F, Robert-Gero M. (1996) Pentamidine uptake in Leishmania donovani and L. amazonensis promastigotes. Biochemistry Journal, 315, 631 -634.
34. Brendle JJ, Outlaw A, Kumar A, Boykin DW, Patrick DA, Tidwell RR, Werbovetz KA. (2002) Antileishmanial activities of several classes of aromatic dications. Antimicrobial Agents and Chemotherapy, 46, 797-807.
35. Antony JP, Fyfe L, Smith H. (2005) Plant active components a resource for antiparasitic agents? Trends in Parasitology, 21, 462-468.